Yonglin Liu, Ph.D., is a member of the IP procurement and portfolio management practice group and USPTO registered. As an experienced associate, Yonglin has provided strategic legal and business advice to leading pharmaceutical and health care companies, mid-size companies, start-ups, and universities and research institutes, pertaining to patent prosecution and patent portfolio management. Yonglin routinely provides guidance to clients on developing portfolios for critical assets and helps devise strategies for expanding protections on existing portfolios; and regularly performs prior art, landscape, and freedom-to-operate searches as part of his evaluation of patentability and freedom-to-operate issues, and prepares patentability, validity, and freedom-to-operate opinions for portfolio analyses and investment due diligence.
Yonglin has prepared and prosecuted global patent applications for public institutions and private pharmaceutical, health care and medical device companies in the fields of pharmaceutical, chemical, materials science and engineering, nanotechnology/nanomaterials, biotechnology, and other life science technologies, along with biomedical and mechanical equipment. He has assisted clients to secure patents in the fields of pharmaceuticals, small-molecule drugs, polymorphs, and related formulations, vaccine technology, catalysts, natural products, polymers, nanomaterials, lubricants, surfactants, recombinant proteins, therapeutic antibodies, medical devices, drug delivery systems, diagnostic systems and others.
Yonglin holds a Ph.D. in organic chemistry from Johns Hopkins University and Yonglin's Ph.D. research focused on the rational design organic molecules as precursors to reactive intermediates and included design and multi-step synthesis of novel organic molecules and functional macromolecules for use in studies of the reactive intermediates. Yonglin is an author of many prestigious publications, including those from Angew. Chem. Int. Ed. and Nano Letter. He is also a named inventor on an issued US patent.
